A Study of Experimental Medication BMS-986235 in Healthy Subjects
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 12/20/2018 |
| Start Date: | November 14, 2017 |
| End Date: | September 23, 2019 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information |
| Email: | Clinical.Trials@bms.com |
| Phone: | please email: |
Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986235 in Healthy Subjects
This is a study of experimental medication BMS-986235 in healthy subjects.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Patients must be normal healthy volunteers as determined by no clinically significant
deviations in medical history, physical examination, ECGs, vital signs, and clinical
laboratory determinations
- Patients must have a body mass index (BMI) of 18 - 30 mg/kg2, inclusive
Exclusion Criteria:
- Patients that are pregnant
- Patient with any significant acute or chronic medical illness
- Patient with a current or recent (within 3 months of study treatment administration)
gastrointestinal disease that could affect absorption
- Patient with any surgery within 12 weeks of study treatment administration
- Patient with any gastrointestinal surgery that could impact upon the absorption of
study drug
- Patient who donated blood to a blood bank or in a clinical study (except a screening
visit) within 12 weeks of study drug administration (within 2 weeks for plasma only)
- Patient who received a blood transfusion within 12 weeks of study drug administration
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
1
site
Click here to add this to my saved trials
